上田 一奈太 (ウエダ ヒナタ)

薬学研究院 医療薬学部門 医療薬学分野助教

研究者基本情報

■ 学位
  • 博士(臨床薬学), 北海道大学, 2025年03月
■ URL
researchmap URLホームページURL■ ID 各種
ORCID IDJ-Global ID■ 研究キーワード・分野
研究分野
  • ライフサイエンス, 薬系衛生、生物化学, 薬物動態学、医療薬学
■ 担当教育組織

経歴

■ 経歴
経歴
  • 2025年04月 - 現在
    北海道大学, 大学院薬学研究院, 助教
  • 2023年04月 - 現在
    札幌薬剤師会, 学校薬剤師
  • 2023年04月 - 2025年03月
    独立行政法人日本学術振興会, 特別研究員 (DC2)
学歴
  • 2021年04月 - 2025年03月, 北海道大学, 大学院生命科学院, 臨床薬学専攻, 日本国
  • 2015年04月 - 2021年03月, 北海道大学, 薬学部, 薬学科, 日本国

研究活動情報

■ 受賞
  • 2025年06月, 日本医療薬学会, Postdoctoral Award
  • 2024年10月, 第18回 次世代を担う若手のための医療薬科学シンポジウム, 優秀発表賞
  • 2023年03月, 優秀演題発表賞
    日本薬学会 第143年会
  • 2022年06月, 優秀演題発表賞 日本医療薬学会 第5回 フレッシャーズ・カンファランス
■ 論文
  • Inhibition and Knockdown of Monocarboxylate Transporter 1 Induce L-Lactate Accumulation in T-Cell Acute Lymphoblastic Leukemia Cells
    Yudai Suganuma; Yuto Mukai; Noriyuki Matsumoto; Atsushi Yamaguchi; Hinata Ueda; Keisuke Okamoto; Katsuya Narumi; Masaki Kobayashi
    Biological and Pharmaceutical Bulletin, 49, 10, 1616, 1622, Pharmaceutical Society of Japan, 2026年10月06日, [査読有り]
    研究論文(学術雑誌)
  • UPLC–MS/MS method for quantifying non-stimulant ADHD medications in human breast milk and plasma: Application in a lactating patient receiving atomoxetine
    Ryoichi Aoyagi; Ayako Furugen; Ayako Nishimura; Takeshi Umazume; Shuhei Ishikawa; Katsuya Narumi; Keisuke Okamoto; Hinata Ueda; Masaki Kobayashi
    Journal of Pharmaceutical and Biomedical Analysis, 2026年10月, [査読有り]
    研究論文(学術雑誌)
  • Involvement of Protein Kinase C Delta and Monocarboxylate Transporter 4 in the Development of Statin-Induced Cytotoxicity in a Rhabdomyosarcoma-Derived Cell Line
    Keisuke Okamoto; Toya Matsui; Yurika Kikutani; Hinata Ueda; Ayako Furugen; Katsuya Narumi; Masaki Kobayashi
    Biological and Pharmaceutical Bulletin, 49, 9, 1438, 1443, Pharmaceutical Society of Japan, 2026年09月05日, [査読有り]
    研究論文(学術雑誌)
  • Everolimus Breast Milk Transfer After Liver Transplantation
    Nozomi Yoshimoto; Hinata Ueda; Masaki Kobayashi; Katsuya Narumi; Keisuke Okamoto; Satoshi Matsuzawa; Kayo Tomimori; Michika Yamaguchi; Naoki Yoshikawa; Ryuji Ikeda; Shinji Katsuragi
    Breastfeeding Medicine, SAGE Publications, 2026年08月23日, [査読有り]
    研究論文(学術雑誌), Background:

    Improving survival after liver transplantation has increased pregnancy rates among women of reproductive age, raising critical questions about breastfeeding safety with maintenance immunosuppressants. Quantitative human data on everolimus transfer into breast milk remain extremely limited.

    Methods:

    Pharmacokinetic assessment of everolimus (0.25 mg/day once daily) was performed in a woman postpartum day 5 after cesarean delivery. Maternal whole-blood and breast milk samples were collected under steady-state conditions. Whole-blood concentrations were measured by automated immunoassay; breast milk concentrations were quantified by liquid chromatography–tandem mass spectrometry (LC–MS/MS).

    Results:

    Maternal whole-blood concentrations peaked at 4 hours (1.98 ng/mL). Breast milk concentrations showed a delayed peak at 9 hours (0.117 ng/mL). Using the linear trapezoidal method, the milk-to-whole-blood AUC0-24 ratio was 0.078, and the estimated relative infant dose (RID) was 0.30%.

    Conclusion:

    This first liver transplant case demonstrates minimal transfer of everolimus into breast milk, with an estimated RID of 0.30% and delayed mammary peak kinetics. High-sensitivity LC-MS/MS enabled reliable quantification even at minimal maternal doses. Although limited to a single case, these findings provide clinically relevant human pharmacokinetic data to support individualized breastfeeding counseling in everolimus-treated liver transplant recipients.
  • Automating the roter interaction analysis system for medication counseling: A transformer-based deep learning approach with generative AI-augmented data
    Ayako Mori; Satoshi Watabe; Izumi Kato; Katsuya Narumi; Yoh Takekuma; Hayato Kizaki; Shungo Imai; Keisuke Okamoto; Hinata Ueda; Mitsuru Sugawara; Satoko Hori; Masaki Kobayashi
    Research in Social and Administrative Pharmacy, Elsevier BV, 2026年06月, [査読有り]
    研究論文(学術雑誌)
  • Ganoderic Acid A Derived from Reishi Mushroom <i>Ganoderma lucidum</i> Protects against Intestinal Immunity Reduction Due to Oxidative Stress in Rat
    Atsuhito Kubota; Keisuke Okamoto; Genki Yasuda; Katsuya Narumi; Yuji Suzuki; Hinata Ueda; Ayako Mori; Natsuko Takahashi-Suzuki; Takashi Satoh; Ken Iseki; Masaki Kobayashi
    Biological and Pharmaceutical Bulletin, 49, 4, 701, 707, Pharmaceutical Society of Japan, 2026年04月14日, [査読有り]
    研究論文(学術雑誌)
  • Placental transfer of third-generation antiepileptic drugs: in vivo lacosamide case study and in vitro investigation of transporter inhibition by lacosamide and perampanel.
    Ayami Ueda; Ayako Furugen; Ayako Nishimura; Takeshi Umazume; Ryoichi Aoyagi; Keisuke Okamoto; Katsuya Narumi; Hinata Ueda; Masaki Kobayashi
    Journal of pharmaceutical health care and sciences, 2026年01月24日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌)
  • Evaluation of intestinal absorption of deoxyribonucleic acid components in salmon milt extract using in-situ and in vitro gastrointestinal absorption models.
    Rin Taguchi; Katsuya Narumi; Hinata Ueda; Hiroshi Satoh; Takao Mori; Keisuke Okamoto; Ayako Furugen; Masaki Kobayashi
    Bioscience, biotechnology, and biochemistry, 2026年01月09日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Salmon milt extract (SME) is rich in deoxyribonucleic acids and has been suggested as a functional material. However, whether these components contribute to SME's functionality remains unclear, and data on their intestinal absorption are limited. This study investigated absorption mechanisms of deoxyribonucleic acid components in SME using in-situ and in vitro models. UPLC-MS/MS was used to simultaneously quantify four deoxyribonucleosides (dNs). The in-situ rat intestinal loop study showed increased levels of 2'-deoxyadenosine (dAdo) and 2'-deoxyguanosine (dGuo) in the portal vein. In the transcellular transport assay, dAdo and dGuo levels on the receiver side increased in a time-dependent manner after SME treatment, particularly in human induced pluripotent stem cell-derived small intestinal epithelial cells. No increase in 2'-deoxycytidine or thymidine levels was observed under any experimental condition. These results indicate that purine dNs are absorbed into the portal vein after oral intake of SME, whereas intestinal absorption of pyrimidine dNs is limited.
  • Quetiapine competitively inhibits aldehyde oxidase-mediated reduction.
    Hinata Ueda; Shuho Asano; Katsuya Narumi; Ryoichi Aoyagi; Keisuke Okamoto; Masaki Kobayashi
    Drug metabolism and disposition: the biological fate of chemicals, 53, 11, 100169, 100169, 2025年09月24日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), Aldehyde oxidase (AOX) oxidizes nitrogen-containing heterocyclic drugs and reduces electron-deficient nitroaromatic drugs. The aim of this study was to elucidate the mode of inhibition of benzothiazepines such as quetiapine and clozapine, which are known inhibitors of AOX, to predict drug-drug interactions between AOX substrates and inhibitors. Quetiapine and its metabolites inhibited the oxidation and reduction activities of AOX (inhibitory effects: quetiapine ≈ norquetiapine > quetiapine sulfoxide > quetiapine carboxylic acid). The inhibition mode of quetiapine was noncompetitive for phthalazine oxidation (Ki, 5.72 ± 0.88 μM) and competitive for flunitrazepam reduction (Ki, 5.71 ± 0.34 μM). Although a mixed inhibition mode was indicated for the reduction of AOX by clozapine (Ki, 30.91 ± 4.02 μM), the affinity for the enzyme-substrate complex was estimated to be lower than its affinity for the substrate-free enzyme. On the basis of these results, we expected that benzothiazepines would inhibit activity by becoming trapped in the pocket of AOX, where the electron donor resides. Quetiapine and its metabolites did not inhibit xanthine oxidase activity, and it is assumed that there are significant structural differences in the sites where the reduction reactions of AOX and xanthine oxidase occur. To our knowledge, this is the first study to identify drugs that competitively inhibit the AOX-mediated reduction reactions. The affinities of the inhibitors, especially quetiapine, were higher than those of flunitrazepam used in this study. When evaluating the combined effects of competitive inhibitors on substrate drugs, attention should be paid to the concentrations of both the substrate and the inhibitor. SIGNIFICANCE STATEMENT: Quetiapine inhibited the oxidative reaction of aldehyde oxidase noncompetitively and the reductive reaction competitively, suggesting that benzothiazepines tend to bind to the reductive pocket of aldehyde oxidase.
  • Effect of Acid Suppressants on Adverse Events of Immune Checkpoint Inhibitors Using Real-world Databases.
    Keisuke Okamoto; Juri Takizawa; Hinata Ueda; Katsuya Narumi; Masaki Kobayashi
    Anticancer research, 45, 8, 3287, 3293, 2025年08月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND/AIM: Immune checkpoint inhibitors (ICIs) cause immune-related adverse events (irAEs) in various organs. Although many studies have suggested that acid suppressants (ASs) may affect irAEs, limited sample sizes have hindered detailed evaluations. Therefore, this study aimed to assess the impact of ASs on individual irAEs using large real-world databases, the Japanese Adverse Drug Event Report database (JADER) and the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). MATERIALS AND METHODS: We analyzed adverse event (AE) reports from the JADER and FAERS databases to assess the impact of ASs on ICI-related AEs. Reporting odds ratios (RORs) and 95% confidence intervals (95%CI) were calculated. Drug-drug interaction signals were defined by non-overlapping 95%CIs between ICIs alone and their combination use. RESULTS: Co-administration with ASs or proton pump inhibitors (PPIs) was associated with an increased risk of acute kidney injury (AKI) in both datasets, while H2-receptor antagonists (H2RAs) showed weaker or no signals. The incidence of endocrine-related AEs tended to decrease with ASs. The colitis results differed between the two datasets, with a decreased incidence in the JADER and an increased incidence in FAERS. Other ICI-related AEs showed consistent trends across datasets. Subgroup analyses of individual PPIs revealed varying results for AKI and colitis between the JADER and FAERS databases, with no consistent trends across PPIs. CONCLUSION: ASs have diverse effects on ICI-induced AEs and their characteristics may differ between PPIs and H2RAs.
  • Evaluation of the Effect of Aldehyde Oxidase Inhibitors on 6-Mercaptopurine Metabolism.
    Hinata Ueda; Katsuya Narumi; Ayako Furugen; Keisuke Okamoto; Yoshitaka Saito; Masaki Kobayashi
    Biological & pharmaceutical bulletin, 48, 5, 713, 720, 2025年, [査読有り], [筆頭著者], [国内誌]
    英語, 研究論文(学術雑誌), Thiopurines, such as 6-mercaptopurine (6-MP) and azathioprine, are converted to the inactive metabolites 6-thioxanthin (6-TX) and 6-thiouric acid (6-TUA). Molybdenum-containing oxidoreductases, aldehyde oxidase (AOX) and xanthine oxidase (XO), are involved in the oxidation of 6-MP to 6-TX; XO inhibitors affect the therapeutic efficacy of thiopurines and the incidence of adverse effects, such as liver and blood disorders. However, the role of AOX in the pharmacokinetics of 6-MP remains unclear. To clarify the clinical importance of AOX-mediated drug-drug interactions, we evaluated whether drugs that inhibit AOX affect 6-MP metabolism. The metabolism of 6-MP to 6-TX was strongly inhibited by AOX inhibitors (amitriptyline, chlorpromazine, clomipramine, clozapine, hydralazine, quetiapine, and raloxifene) in a reaction mixture containing human liver cytosol. The inhibition of 6-TX production rate by each AOX inhibitor was 60-70% at high concentrations, although the XO inhibitor febuxostat showed an inhibition rate of 10-30%. Furthermore, the combination of febuxostat and each AOX inhibitor showed greater inhibition than when each compound was added alone. The AOX inhibitor did not alter 6-MP oxidation by recombinant XO. These results suggest that AOX inhibition may affect the pharmacokinetics of thiopurines. However, because of the lower activity of AOX in rats than that in humans, the contribution of AOX could not be assessed using in vivo experiments. Further studies are needed to evaluate the contribution of AOX to the therapeutic and adverse effects of thiopurines, both in clinical studies and in animal models of liver humanization.
  • Contribution of aldehyde oxidase to methotrexate-induced hepatotoxicity: In Vitro and pharmacoepidemiological approaches.
    Ayako Moriyama; Hinata Ueda; Katsuya Narumi; Shuho Asano; Ayako Furugen; Yoshitaka Saito; Masaki Kobayashi
    Expert opinion on drug metabolism & toxicology, 2024年05月06日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Methotrexate (MTX) is partially metabolized by aldehyde oxidase (AOX) in the liver and its clinical impact remains unclear. In this study, we aimed to demonstrate how AOX contributes to MTX-induced hepatotoxicity in vitro and clarify the relationship between concomitant AOX inhibitor use and MTX-associated liver injury development using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: We assessed intracellular MTX accumulation and cytotoxicity using HepG2 cells. We used the FAERS database to detect reporting odds ratio (ROR)-based MTX-related hepatotoxicity event signals. RESULTS: AOX inhibition by AOX inhibitor raloxifene and siRNA increased the MTX accumulation in HepG2 cells and enhanced the MTX-induced cell viability reduction. In the FAERS analysis, the ROR for MTX-related hepatotoxicity increased with non-overlap of 95% confidence interval when co-administered with drugs with higher Imax, u (maximum unbound plasma concentration)/IC50 (half-maximal inhibitory concentration for inhibition of AOX) calculated based on reported pharmacokinetic data. CONCLUSION: AOX inhibition contributed to MTX accumulation in the liver, resulting in increased hepatotoxicity. Our study raises concerns regarding MTX-related hepatotoxicity when co-administered with drugs that possibly inhibit AOX activity at clinical concentrations.
  • Comparative study on the occurrence of adverse effects in the concomitant use of azathioprine and aldehyde oxidase inhibitors.
    Hinata Ueda; Katsuya Narumi; Shuho Asano; Yoshitaka Saito; Ayako Furugen; Masaki Kobayashi
    Expert opinion on drug safety, 2023年12月14日, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), OBJECTIVES: Aldehyde oxidase (AO) is a molybdenum-containing redox enzyme similar to xanthine oxidase that is involved in the thiopurine metabolism. This study investigated the effects of drug-drug interactions (DDIs) between azathioprine (AZA) and AO inhibitors on hematologic and hepatic disorders using the U.S. Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report database. METHODS: The presence of DDI was assessed using the interaction signal scores (ISSs) calculated via the reporting odds ratios and 95% confidence intervals. The study used reports of 'azathioprine' as a suspect drug for adverse effects. AO inhibitors were selected based on previous in vitro reports. RESULTS: Some drugs tested positive for ISSs in each database and type of adverse effect (hematologic or hepatic disorder) analysis. Among these drugs, chlorpromazine, clozapine, hydralazine, and quetiapine could inhibit AZA metabolism via AO, given the previously reported clinical blood concentration and inhibitory effects of each drug. CONCLUSION: Concomitant use of AO inhibitors increased the signals for AZA-induced adverse effects. To date, no studies have evaluated the clinical importance of AO as a drug-metabolizing enzyme, and further in vitro and clinical research is needed to clarify the contribution of AO to the pharmacokinetics of thiopurines.
  • 5-Oxoproline Enhances 4-Hydroxytamoxifen-induced Cytotoxicity by Increasing Oxidative Stress in MCF-7 Breast Cancer Cells.
    Takanobu Nadai; Katsuya Narumi; Yuto Mukai; Hinata Ueda; Ayako Furugen; Yoshitaka Saito; Masaki Kobayashi
    Anticancer research, 43, 3, 1113, 1120, 2023年03月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND/AIM: Monocarboxylate transporters (MCTs) transport short-chain monocarboxylates, such as lactate, and have been reported to be related to poor prognosis in breast cancer. Our previous studies showed that a high glucose state altered MCT expression and changed the sensitivity of the tamoxifen active metabolite 4-hydroxytamoxifen (4-OHT) via hypoxia-inducible factor-1α (HIF-1α) protein expression. We hypothesized that MCT inhibitors affect 4-OHT-induced cytotoxicity under normal glucose conditions by decreasing HIF-1α protein expression. To test this hypothesis, we evaluated the combined effect of MCT inhibitor and 4-OHT using the estrogen receptor (ER)-positive breast cancer cell line MCF-7, under normal glucose conditions. MATERIALS AND METHODS: Expression of MCTs and oxidative stress markers was evaluated by real-time PCR. Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Reactive oxygen species (ROS) were measured using the cell permeability probe 2',7'-dichlorodihydrofluorescein diacetate. RESULTS: MCT1 expression increased under normal glucose conditions. The MCT1 substrate/inhibitor, 5-oxoproline (5-OP), enhanced 4-OHT-induced cytotoxicity. Bindarit, a selective MCT4 inhibitor, decreased 4-OHT sensitivity, similar to results of our previous study under high glucose conditions. In contrast, the combination of 5-OP and 4-OHT decreased ATP levels compared with that by 4-OHT alone in MCF-7 cells. Furthermore, 5-OP significantly increased the ROS production induced by 4-OHT. CONCLUSION: 5-OP enhances 4-OHT-induced cytotoxicity in ER-positive breast cancer cells under normal glucose conditions.
  • The rs35217482 (T755I) single-nucleotide polymorphism in aldehyde oxidase-1 attenuates protein dimer formation and reduces the rates of phthalazine metabolism
    Hinata Ueda; Katsuya Narumi; Ayako Furugen; Yoshitaka Saito; Masaki Kobayashi
    Drug Metabolism and Disposition, DMD, AR, American Society for Pharmacology & Experimental Therapeutics (ASPET), 2022年07月16日, [査読有り], [筆頭著者]
    英語, 研究論文(学術雑誌)
  • Diclofenac potentiates the antitumor effect of cisplatin in a xenograft mouse model transplanted with cisplatin-resistant cells without enhancing cisplatin-induced nephrotoxicity.
    Keisuke Okamoto; Hinata Ueda; Yoshitaka Saito; Katsuya Narumi; Ayako Furugen; Masaki Kobayashi
    Drug metabolism and pharmacokinetics, 41, 100417, 100417, 2021年12月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Cisplatin (CDDP) is a well-known anticancer agent, and CDDP-induced nephrotoxicity (CIN) is one of the most serious adverse effects. Previously, we revealed that while celecoxib reduces CIN, diclofenac does not appear to enhance it. Furthermore, we reported that diclofenac additively enhances the cytotoxic effect of CDDP on CDDP-resistant A549 cells (A549/DDP cells) and their spheroids. In addition, celecoxib reduces the cytotoxic effect of CDDP on A549/DDP cells while demonstrating an anticancer effect; however, it enhanced the effect of CDDP cytotoxicity on spheroids. Therefore, we evaluated the effects of diclofenac or celecoxib on CIN and the antitumor effect of CDDP in a xenograft mouse model transplanted with A549/DDP cells. Although CDDP did not decrease tumor size and tumor weight, these parameters were significantly reduced following co-administration with diclofenac when compared with the control group. Conversely, celecoxib marginally suppressed the antitumor effect of CDDP. Moreover, CDDP increased the mRNA levels of kidney injury molecule 1 (Kim-1), a renal disorder marker, in the kidneys of xenograft mice; treatment with celecoxib and diclofenac did not impact Kim-1 mRNA levels increased by CDDP. In conclusion, diclofenac potentiated the antitumor effect of CDDP without enhancing CIN.
  • In vitro and in vivo evaluation of organic anion-transporting polypeptide 2B1-mediated pharmacokinetic interactions by apple polyphenols.
    Yuka Takahashi; Katsuya Narumi; Takanobu Nadai; Hinata Ueda; Taiki Yamamura; Ayako Furugen; Masaki Kobayashi
    Xenobiotica; the fate of foreign compounds in biological systems, 51, 11, 1318, 1325, 2021年11月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Organic anion-transporting polypeptide (OATP) 2B1 plays a critical role in the intestinal absorption of substrate drugs. Apple juice reportedly interacts with OATP2B1 substrate drugs. The purpose of this study was to investigate the effect of two apple polyphenols, phloretin and phloridzin, on OATP2B1-mediated substrate transport in vitro and to evaluate the effect of phloretin on rosuvastatin pharmacokinetics in rats.In vitro studies revealed that both polyphenols inhibited OATP2B1-mediated uptake of estrone-3-sulfate. Despite preincubation with phloretin and subsequent washing, the inhibitory effect was retained. Phloretin markedly decreased OATP2B1-mediated rosuvastatin uptake, with an IC50 value of 3.6 μM.On coadministering rosuvastatin and phloretin in rats, the plasma concentration of rosuvastatin 10 min after oral administration was significantly lower than that in the vehicle group. The area under the plasma concentration-time curve of rosuvastatin was not significant, showing a tendency to decrease in the phloretin group when compared with the vehicle group. The in-situ rat intestinal loop study revealed the inhibitory effect of phloretin on rosuvastatin absorption.Phloretin has potent and long-lasting inhibitory effects on OATP2B1 in vitro. Phloretin may inhibit OATP2B1-mediated intestinal absorption of rosuvastatin; however, it failed to significantly impact the systemic exposure of rosuvastatin in rats.
  • Antioxidant effect of ascorbic acid against cisplatin-induced nephrotoxicity and P-glycoprotein expression in rats.
    Keisuke Okamoto; Fumi Kitaichi; Yoshitaka Saito; Hinata Ueda; Katsuya Narumi; Ayako Furugen; Masaki Kobayashi
    European journal of pharmacology, 909, 174395, 174395, 2021年10月15日, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Cisplatin (CDDP) is a highly potent anticancer drug that is widely used in the treatment of several cancers. CDDP-induced nephrotoxicity (CIN) is one of the most significant adverse effects, and oxidative stress is thought to be one of the mechanisms underlying CIN. Although there are some studies available on the variability in transporter expression in the kidney after a single CDDP dose, none have reported the change in renal transporter expression after multiple CDDP dose administrations. P-glycoprotein (P-gp), a transporter, is reported to be induced by oxidative stress. Ascorbic acid is a vitamin with antioxidant potential and therefore, may regulate the expression of P-gp transporter and affect CIN. In the present study, our aim was to assess the variability in expression of several renal transporters after multiple CDDP dose administrations and the antioxidant effect of ascorbic acid against transporter expression and CIN. Multiple doses of CDDP affected markers of kidney injury and antioxidants in the kidneys. Also, the expression of P-gp, breast cancer resistance protein, and multidrug resistance-associated protein 4 was upregulated by CDDP. Using a normal kidney cell line, we demonstrated that ascorbic acid attenuated CDDP-induced cytotoxicity due to its high superoxide scavenging ability. CDDP and ascorbic acid were injected into rats once a week for three weeks, and it was observed that co-administration of ascorbic acid attenuated CIN and regulated antioxidant marker. In addition, ascorbic acid reduced P-gp expression, which was upregulated by CDDP. In conclusion, ascorbic acid may attenuate CIN and reverse P-gp-mediated changes in drug pharmacokinetics.
  • Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells.
    Keisuke Okamoto; Yoshitaka Saito; Hinata Ueda; Katsuya Narumi; Ayako Furugen; Masaki Kobayashi
    Biopharmaceutics & drug disposition, 42, 8, 389, 392, 2021年09月, [査読有り], [国際誌]
    英語, 研究論文(学術雑誌), Cystine/glutamate transporter (xCT) is an antiporter involved in cystine uptake and glutamate efflux. However, there are very few reports regarding the kinetic analysis of xCT for cystine uptake using cancer cell lines, as well as the inhibition pattern of sulfasalazine, an inhibitor of xCT, for cystine uptake. Therefore, the purpose of this study was to clarify the kinetics of xCT in A549 cells, human lung cancer cells, and to reveal the inhibition pattern of sulfasalazine. Cystine uptake occurred in a time-dependent manner, with linear cystine uptake observed for 5 min. Additionally, sulfasalazine inhibited cystine uptake in a concentration-dependent manner, presenting an IC50 value of 24.7 ± 5.6 μM. Cystine uptake was saturated with increasing concentration, demonstrating Km and Vmax values of 179.4 ± 26.7 μM and 30.4 ± 2.3 nmol/min/mg protein, respectively. Moreover, during cystine uptake with sulfasalazine, Km and Vmax were >300 μM and 8.0 ± 1.5 nmol/min/mg protein, respectively, suggesting that sulfasalazine might demonstrate a mixed inhibition pattern. Furthermore, xCT siRNA decreased the xCT mRNA level and reduced cystine uptake. In conclusion, xCT was involved in the cystine uptake in A549 cells and sulfasalazine showed a mixed inhibition pattern to xCT.
  • Evaluation of possible pharmacokinetic interaction between methotrexate and proton pump inhibitors in rats.
    Hinata Ueda; Katsuya Narumi; Yu Sato; Ayako Furugen; Masaki Kobayashi; Ken Iseki
    Pharmacological reports : PR, 72, 5, 1426, 1432, 2020年10月, [査読有り], [筆頭著者], [国際誌]
    英語, 研究論文(学術雑誌), BACKGROUND: Methotrexate (MTX), an antifolate agent, is primarily eliminated by the kidney. Organic anion transporter 3 (OAT3) contributes to renal MTX clearance. Several studies have shown an association between co-administration of proton pump inhibitors (PPIs) and delayed elimination of MTX, but the findings are conflicting. In this study, we aimed to evaluate whether the differential inhibitory effects of PPIs on the OAT3-mediated transport of MTX are associated with the risks of delayed MTX elimination. METHODS: We investigated the effects of PPIs on rat (r) OAT3-mediated MTX uptake using HEK293T cells expressing rOAT3. To examine whether PPIs could affect the pharmacokinetics of MTX, changes in plasma concentration-time profiles were assessed when MTX (50 mg/kg, ip) and a range of PPIs (2 mg/kg, iv) were administered to rats. RESULTS: In vitro studies demonstrated that PPIs inhibited rOAT3-mediated uptake of MTX, with estimated IC50 values of 2.1-5.2 μM, and a rank order of esomeprazole ≈ lansoprazole ≈ omeprazole > rabeprazole. When MTX and esomeprazole were co-administered to rats, the plasma concentration of MTX 6 h after administration and the t1/2 were significantly higher than those in the vehicle group. The effect of lansoprazole was not significant, but showed a tendency to prolong plasma MTX levels. Famotidine, a histamine H2-receptor antagonist, showed a weak inhibitory effect on rOAT3-mediated MTX uptake, although it did not affect plasma concentration-time profile of MTX in vivo. CONCLUSION: Esomeprazole increases the t1/2 of MTX in rats, which may be partially attributed to the inhibition of rOAT3.
■ その他活動・業績
■ 講演・口頭発表等
  • 肝細胞がんに対するモノカルボン酸輸送担体MCT1/MCT4の二重阻害を基盤とする新規治療戦略の検証
    向井 悠斗; 上田 一奈太; 岡本 敬介; 鳴海 克哉; 山田 勇磨; 小林 正紀
    第20回次世代を担う若手のための医療薬科学シンポジウム, 2026年10月
  • 神経細胞におけるL-乳酸を介したヒストン修飾とモノカルボン酸輸送担体の関連の検証
    向井悠斗; 松本憲之; 菅沼雄大; 中野広大; 石川修平; 上田一奈太; 岡本敬介; 鳴海克哉; 小林正紀
    第14回日本未病学会北海道支部会, 2026年09月
  • 酸化ストレス応答転写因子NRF2によるAOX1発現制御機構の解析
    石橋利矩; 鳴海克哉; 石原孔明; 上田一奈太; 岡本敬介; 小林正紀
    第38回北海道薬物作用談話会, 2026年08月
  • プロトンポンプ阻害薬がカペシタビン起因性手足症候群へ及ぼす影響の評価
    行徳 千歳; 岡本 敬介; 鳴海 克哉; 上田 一奈太; 小林 正紀
    第38回北海道薬物作用談話会, 2026年08月
  • 神経由来細胞におけるMCTsを介したラクチル化制御に関する研究
    松本 憲之; 向井 悠斗; 菅沼 雄大; 中野 広大; 石川 修平; 上田 一奈太; 岡本 敬介; 鳴海 克哉; 小林 正紀
    第38回北海道薬物作用談話会, 2026年08月
  • サケ白子抽出物が腸管上皮防御機構に及ぼす影響
    羽田野友香; 鳴海克哉; 佐藤浩志; 盛孝男; 上田一奈太; 岡本敬介; 小林正紀
    第38回北海道薬物作用談話会, 2026年08月
  • 高尿酸血症治療薬フェブキソスタットの胎盤移行および乳汁移行を評価した一症例
    西村あや子. 上田一奈太. 小林正紀. 細川亜美. 武隈洋. 馬詰武. 菅原満
    第66回日本先天異常学会学術集会, 2026年07月
  • シクロホスファミド関連心毒性の発現に及ぼす酸化還元酵素阻害薬の影響 ~JADER/FAERS解析~
    石原孔明; 鳴海克哉; 上田一奈太; 岡本敬介; 小林正紀
    第18回日本がん薬剤学会(JSOPP)学術大会, 2026年07月
  • シスプラチン起因性腎障害に対するセレコキシブの影響:ロキソプロフェン・ナプロキセンとの後方視比較検証
    岡本敬介; 齋藤佳敬; 高橋健太; 武隈洋; 榊原純; 鳴海克哉; 上田一奈太; 菅原満; 小林正紀
    第18回日本がん薬剤学会(JSOPP)学術大会, 2026年07月
  • MCF10F乳腺上皮モデルを用いたADHD治療薬atomoxetineの乳汁移行性と寄与因子の検討
    青栁 亮一; 古堅 彩子; 鳴海 克哉; 岡本 敬介; 上田 一奈太; 小林 正紀
    第9回フレッシャーズ・カンファランス, 2026年07月
  • モノカルボン酸輸送担体(MCTs)のがん予後因子としてのメタ解析及びデータベース・in vitro 解析による機能的検証
    菅沼 雄大; 向井 悠斗; 松本 憲之; 山口 敦史; 上田 一奈太; 岡本 敬介; 鳴海 克哉; 小林 正紀
    医療薬学フォーラム2026, 2026年06月20日
  • シクロホスファミド誘発性心毒性における酸化還元酵素の寄与 ーFAERS 解析および基礎的検討ー
    石原 孔明; 鳴海 克哉; 上田 一奈太; 岡本 敬介; 小林 正紀
    医療薬学フォーラム 2026/第 34 回クリニカルファーマシーシンポジウム, 2026年06月20日
  • 胃酸分泌抑制薬が免疫チェックポイント阻害薬による免疫関連有害事象に及ぼす影響の検証
    滝澤 寿莉; 岡本 敬介; 近田 那央; 上田 一奈太; 鳴海 克哉; 小林 正紀
    日本薬学会 北海道支部第152回例会, 2026年05月30日
  • 第三世代抗てんかん薬の胎盤移行性に関する研究
    植田 彩文; 古堅 彩子; 西村 あや子; 馬詰 武; 青栁 亮一; 岡本 敬介; 鳴海 克哉; 上田 一奈太; 小林 正紀
    日本薬学会 北海道支部第153回例会, 2026年05月30日
  • CS分析(Customer Satisfaction analysis)を応用した薬剤業務補助者への研修・教育に対する満足度調査
    菊谷 由里香; 寺田 和文; 森 綾子; 鳴海 克哉; 上田 一奈太; 岡本 敬介; 廣川 力教; 小林 正紀
    第73回北海道薬学大会・北海道病院薬剤師会会員研究発表会, 2026年05月
  • ADHD治療薬のヒト乳汁移行性の解明:ヒト乳汁中薬物濃度解析と乳腺モデル細胞による評価
    青栁 亮一; 古堅 彩子; 西村 あや子; 馬詰 武; 石川 修平; 鳴海 克哉; 岡本 敬介; 上田 一奈太; 小林 正紀
    日本薬学会第146年会, 2026年03月27日
  • 〔主要な業績〕アルデヒドオキシダーゼを介した薬物間相互作用および個体間差に関する研究
    上田一奈太
    第35回日本医療薬学会年会, 2025年11月24日, 日本語, シンポジウム・ワークショップパネル(指名)
    [招待講演]
  • クエチアピンによる AOX 還元反応の阻害を介した薬物相互作用評価―基礎・疫学的アプローチによる検証―
    鳴海 克哉; 上田 一奈太; 淺野 秀峰; 岡本 敬介; 小林 正紀
    第35回日本医療薬学会年会, 2025年11月23日, ポスター発表
  • 基礎・臨床研究によるセレコキシブがシスプラチン起因性腎障害に及ぼす影響の検証
    岡本 敬介; 齋藤 佳敬; 高橋 健太; 武隈 洋; 榊原 純; 鳴海 克哉; 上田 一奈太; 菅原 満; 小林 正紀
    第35回日本医療薬学会年会, 2025年11月22日, 口頭発表(一般)
  • 〔主要な業績〕薬物代謝・副作用データベース解析を活用したチオプリン代謝におけるaldehyde oxidase機能評価
    上田 一奈太; 鳴海 克哉; 岡本 敬介; 古堅 彩子; 小林 正紀
    医療薬学フォーラム 2025/第 33 回クリニカルファーマシーシンポジウム, 2025年06月28日
    2025年06月28日 - 2025年06月29日, [招待講演]
  • 大腸がん治療薬カペシタビンとプロトンポンプ阻害薬の薬物間相互作用の評価
    行徳 千歳; 岡本 敬介; 鳴海 克哉; 上田 一奈太; 小林 正紀
    医療薬学フォーラム 2025/第 33 回クリニカルファーマシーシンポジウム, 2025年06月28日
  • ADHD 治療薬のヒト血漿・乳汁中における UPLC/MS/MS 定量法の構築
    青栁 亮一; 古堅 彩子; 西村 あや子; 馬詰 武; 石川 修平; 鳴海 克哉; 岡本 敬介; 上田 一奈太; 小林 正紀
    医療薬学フォーラム 2025/第 33 回クリニカルファーマシーシンポジウム, 2025年06月28日
  • モノカルボン酸輸送担体の発現とがん患者の予後に関する メタ解析及びin vitroにおける検討
    向井 悠斗; 山口 敦史; 菅沼 雄大; 岡本 敬介; 松本 憲之; 上田 一奈太; 鳴海 克哉; 小林 正紀
    日本医療薬学会 第8回フレッシャーズカンファランス, 2025年06月21日
  • モノカルボン酸輸送担体MCTsの阻害が肝がん細胞株の生存及びエネルギー代謝に与える影響
    松本憲之; 向井悠斗; 菅沼雄大; 村松ゆかり; 山口敦史; 上田一奈太; 岡本敬介; 鳴海克哉; 山田勇磨; 小林正紀
    日本薬学会 北海道支部第152回例会, 2025年05月18日, ポスター発表
  • クエチアピンによるAOX介在性薬物相互作用メカニズムの解明
    淺野秀峰; 上田一奈太; 鳴海克哉; 岡本敬介; 小林正紀
    日本薬学会 北海道支部第152回例会, 2025年05月17日, 口頭発表(一般)
  • T細胞急性リンパ性白血病細胞の乳酸輸送に寄与する輸送担体の同定
    菅沼雄大; 向井悠斗; 松本憲之; 山口敦史; 上田一奈太; 岡本敬介; 鳴海克哉; 小林正紀
    日本薬学会 北海道支部第152回例会, 2025年05月17日, 口頭発表(一般)
  • 〔主要な業績〕アルデヒドオキシダーゼの薬物動態学的重要性および個体間差の解明
    上田一奈太; 鳴海克哉; 岡本敬介; 古堅彩子; 小林正紀
    第18回 次世代を担う若手のための医療薬科学シンポジウム, 2024年10月03日
    2024年10月03日 - 2024年10月04日
  • AOX1遺伝子の5’上流および3’非翻訳領域におけるSNP解析
    林愛; 鳴海克哉; 上田一奈太; 岡本敬介; 古堅彩子; 小林正紀
    第40回日本TDM学会・学術大会, 2024年07月15日
  • メトトレキサート誘発性肝障害におけるアルデヒドオキシダーゼの寄与ー基礎および薬剤疫学的アプローチによる検証ー
    鳴海克哉; 森山綾子; 上田一奈太; 淺野秀峰; 古堅彩子; 小林正紀
    医療薬学フォーラム2023 第31回クリニカルファーマシーシンポジウム, 2023年07月22日
    2023年07月22日 - 2023年07月23日
  • 〔Major achievements〕Effect of aldehyde oxidase inhibitors on azathioprine-induced hematologic and hepatic injury
    Hinata Ueda
    The 143rd Annual Meeting of the Pharmaceutical Society of Japan, 2023年03月, 英語, ポスター発表
  • 〔主要な業績〕アザチオプリン誘発性血液障害および肝障害発現における Aldehyde oxidase 阻害薬剤の影響
    上田一奈太、鳴海克哉、古堅彩子、小林正紀
    日本薬学会 第143年会, 2023年03月, 日本語, ポスター発表
  • メトトレキサート誘発性肝障害における aldehyde oxidase 1 の関与
    森山綾子; 鳴海克哉; 上田一奈太; 古堅彩子; 小林正紀
    第35回 北海道薬物作用談話会, 2022年08月21日
    2022年08月21日
  • 〔主要な業績〕AOX1 遺伝子の T755I 多型は二量体形成および代謝活性を低下させる
    上田一奈太; 鳴海克哉; 古堅彩子; 小林正紀
    日本医療薬学会 第 5 回フレッシャーズ・カンファランス, 2022年06月, 日本語, 口頭発表(一般)
  • シスプラチンの副作用と耐性化に着目した NSAIDs の効果の 検証
    岡本 敬介; 齋藤 佳敬; 上田 一奈太; 古堅 彩子; 鳴海 克哉; 小林 正紀
    日本薬学会 第141年会, 2021年03月
  • 〔主要な業績〕メトトレキサート投与時におけるプロトンポンプ阻害剤の in vivo および in vitro 薬物相互作用評価
    上田一奈太; 鳴海克哉; 古堅彩子; 小林正紀; 井関健
    日本薬学会北海道支部第 147 回例会, 2020年05月, 日本語, 口頭発表(一般)
■ 所属学協会
  • 2023年04月 - 現在
    北海道学校薬剤師会
  • 2023年04月 - 現在
    一般社団法人 札幌薬剤師会
  • 2022年04月 - 現在
    一般社団法人 日本医療薬学会
  • 2020年01月 - 現在
    公益社団法人 日本薬学会
■ 学術・社会貢献活動/その他
その他
  • 2021年10月 - 2023年03月
    Society5.0を牽引するDX博士人材育成のための研究支援プロジェクト
    JST 次世代研究者挑戦的研究プログラム
  • 2021年07月 - 2023年03月
    一般社団法人つくし奨学・研究基金